Senegal
Diabetes country report 2000 — 2050
Skip Map
Number of adults (20–79 years) with diabetes in Senegal (SN)
2000 | 33.5 thousand |
2011 | 146.5 thousand |
2024 | 251.6 thousand |
2050 | 684.8 thousand |
Senegal is one of the 49 countries and territories in the IDF Africa Region.
Data source(s) used for the diabetes estimates in adults:
- WHO STEPS 2015
- Leonard E Egede et al. BMC Public Health. 2021 Jun 12;21(1):1122. doi: 10.1186/s12889-021-11218-5. PMID:34118912
2000
2011
2024
2050
Loading...
Diabetes estimates (20-79 y) | ||||
---|---|---|---|---|
People with diabetes, in 1,000s | 33.5 | 146.5 | 251.6 | 684.8 |
Age-standardised prevalence of diabetes, % | - | 3.2 | 3.8 | 4.6 |
Proportion of people with undiagnosed diabetes, % | - | - | 78.7 | - |
People with undiagnosed diabetes, in 1,000s | - | - | 198.0 | - |
Impaired Fasting Glucose (IFG) | ||||
---|---|---|---|---|
People with IFG, in 1,000s | - | - | 158.6 | 383.5 |
Age-standardised prevalence of IFG, % | - | - | 2.0 | 2.3 |
Impaired Glucose Tolerance (IGT) | ||||
---|---|---|---|---|
People with IGT, in 1,000s | - | 603.4 | 776.4 | 1,757.3 |
Age-standardised prevalence of IGT, % | - | 11.7 | 9.6 | 9.9 |
Mortality attributable to diabetes (20-79 y) | ||||
---|---|---|---|---|
Deaths attributable to diabetes | - | 1,694.0 | 1,186.4 | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 2.0 | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
---|---|---|---|---|
Live births affected by HIP | - | - | - | - |
Prevalence of gestational diabetes mellitus (GDM), % | - | - | - | - |
Live births affected by other types of diabetes first detected in pregnancy | - | - | - | - |
Live births affected by other types of diabetes detected prior to pregnancy | - | - | - | - |
Diabetes-related health expenditure | ||||
---|---|---|---|---|
Total diabetes-related health expenditure, USD million | - | - | 64.2 | 151.5 |
Total diabetes-related health expenditure, ID million | - | - | 159.5 | 376.5 |
Diabetes-related health expenditure per person, USD | - | 111.0 | 255.1 | 221.2 |
Diabetes-related health expenditure per person, ID | - | - | 634.1 | 549.8 |
Type 1 diabetes estimates in children and adolescents | ||||
---|---|---|---|---|
People with type 1 diabetes (all age groups) | - | - | 6,340.0 | - |
People with type 1 diabetes (0-19 y) | - | - | 1,582.8 | - |
Demographics | ||||
---|---|---|---|---|
Total adult population (20-79 y), in 1,000s | 4,219.0 | 5,785.5 | 8,743.4 | 18,543.3 |
Population of children and adolescents (0-19 y) | - | - | 9,114,068.5 | - |
Loading...
Diabetes estimates (20-79 y) | |
---|---|
People with diabetes, in 1,000s | 33.5 |
Age-standardised prevalence of diabetes, % | - |
Proportion of people with undiagnosed diabetes, % | - |
People with undiagnosed diabetes, in 1,000s | - |
Impaired Fasting Glucose (IFG) | |
---|---|
People with IFG, in 1,000s | - |
Age-standardised prevalence of IFG, % | - |
Impaired Glucose Tolerance (IGT) | |
---|---|
People with IGT, in 1,000s | - |
Age-standardised prevalence of IGT, % | - |
Mortality attributable to diabetes (20-79 y) | |
---|---|
Deaths attributable to diabetes | - |
Proportion of diabetes-related deaths in people 20-79 y, % | - |
Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
---|---|
Live births affected by HIP | - |
Prevalence of gestational diabetes mellitus (GDM), % | - |
Live births affected by other types of diabetes first detected in pregnancy | - |
Live births affected by other types of diabetes detected prior to pregnancy | - |
Diabetes-related health expenditure | |
---|---|
Total diabetes-related health expenditure, USD million | - |
Total diabetes-related health expenditure, ID million | - |
Diabetes-related health expenditure per person, USD | - |
Diabetes-related health expenditure per person, ID | - |
Type 1 diabetes estimates in children and adolescents | |
---|---|
People with type 1 diabetes (all age groups) | - |
People with type 1 diabetes (0-19 y) | - |
Demographics | |
---|---|
Total adult population (20-79 y), in 1,000s | 4,219.0 |
Population of children and adolescents (0-19 y) | - |